EDIT logo

Editas Medicine Inc. (EDIT)

$1.83

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on EDIT

Market cap

$281670040

EPS

-0.53

P/E ratio

--

Price to sales

9.48

Dividend yield

--

Beta

2.085838

Price on EDIT

Previous close

$1.87

Today's open

$1.90

Day's range

$1.82 - $1.94

52 week range

$1.66 - $3.94

Profile about EDIT

CEO

Gilmore ONeill

Employees

87

Headquarters

Cambridge, MA

Exchange

Nasdaq Global Select

Shares outstanding

154339748

Issue type

Common Stock

EDIT industries and sectors

Healthcare

Biotechnology & Life Sciences

News on EDIT

Editas Medicine Plans Human Trial After Gene Therapy Slashed LDL 90% in Primate Study

Editas Medicine NASDAQ: EDIT expects to dose the first patients this year in a Phase I/II study of its lead gene-editing candidate, EDIT-401, as the company focuses its development strategy on in vivo CRISPR therapies.

news source

MarketBeat • Nov 10, 2026

news preview

Editas Medicine Announces Third Quarter 2026 Results and Business Updates

Company received HREC approval to initiate Phase 1/2 Strive™ study of EDIT-401 in patients with hyperlipidemia in Australia New preclinical data presented at AHA Scientific Sessions demonstrating ≥90 percent LDL-C reduction maintained over 10 months supports EDIT-401's potential best-in-class profile Second IND/CTA accepted for CD70 HD Allo CAR T program as part of collaboration with Bristol Myers Squibb, triggering milestone payment to Editas Cash runway into second half of 2028, through and beyond key clinical readouts from Strive study CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the third quarter 2026 and provided business updates.

news source

GlobeNewsWire • Nov 9, 2026

news preview

Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates

Editas Medicine (EDIT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.28 per share a year ago.

news source

Zacks Investment Research • Nov 9, 2026

news preview

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, to be held October 27-30, 2026, in Hamburg, Germany.

news source

GlobeNewsWire • Oct 14, 2026

news preview

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia

Editas Medicine gains approval to launch the first-in-human phase I/II study of EDIT-401 in Australia, targeting LDL cholesterol through gene editing.

news source

Zacks Investment Research • Oct 9, 2026

news preview

Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia

Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering  Company remains on track to begin patient dosing this year and report initial safety and tolerability data in the first quarter of 2027 New EDIT-401 preclinical data demonstrating durability of LDL-C reduction to be presented in oral presentation at AHA Scientific Sessions 2026 CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced it has received approval to initiate the Phase 1/2 Strive™ clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH) in Australia.

news source

GlobeNewsWire • Oct 8, 2026

news preview

Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy

Editas Medicine NASDAQ: EDIT outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for lowering LDL cholesterol.

news source

MarketBeat • Sep 12, 2026

news preview

Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401

Editas Medicine NASDAQ: EDIT is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, Chief Executive Officer Gilmore O'Neill said during a Wells Fargo discussion.

news source

MarketBeat • Sep 9, 2026

news preview

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an inducement award to the Company's newly appointed Chief Medical Officer, Daniel Ory, M.D.

news source

GlobeNewsWire • Sep 9, 2026

news preview

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development

news source

GlobeNewsWire • Sep 8, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Editas Medicine Inc.

Open an M1 investment account to buy and sell Editas Medicine Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in EDIT on M1